Literature DB >> 18390751

A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

Amit Gaggar1, Patricia L Jackson, Brett D Noerager, Philip J O'Reilly, D Brent McQuaid, Steven M Rowe, J P Clancy, J Edwin Blalock.   

Abstract

Chronic neutrophilic inflammation is a manifestation of a variety of lung diseases including cystic fibrosis (CF). There is increasing evidence that fragments of extracellular matrix proteins, such as collagen and elastin, play an important role in inflammatory cell recruitment to the lung in animal models of airway inflammation. Unfortunately, the association of these peptides with human disease and the identification of therapeutic targets directed toward these inflammatory pathways have remained elusive. In this study, we demonstrate that a novel extracellular matrix-derived neutrophil chemoattractant, proline-glycine-proline (PGP), acts through CXC receptors 1 and 2 on neutrophils, similar to N-acetylated proline-glycine-proline (N-alpha-PGP). We describe the specific multistep proteolytic pathway involved in PGP generation from collagen, involving matrix metalloproteases 8 and 9 and prolyl endopeptidase, a serine protease for which we identify a novel role in inflammation. PGP generation correlates closely with airway neutrophil counts after administration of proteases in vivo. Using CF as a model, we show that CF sputum has elevated levels of PGP peptides and that PGP levels decline during the course of CF inpatient therapy for acute pulmonary exacerbation, pointing to its role as a novel biomarker for this disease. Finally, we demonstrate that CF secretions are capable of generating PGP from collagen ex vivo and that this generation is significantly attenuated by the use of inhibitors directed toward matrix metalloprotease 8, matrix metalloprotease 9, or prolyl endopeptidase. These experiments highlight unique protease interactions with structural proteins regulating innate immunity and support a role for these peptides as novel biomarkers and therapeutic targets for chronic, neutrophilic lung diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390751      PMCID: PMC3998665          DOI: 10.4049/jimmunol.180.8.5662

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Cystic fibrosis.

Authors:  Steven M Rowe; Stacey Miller; Eric J Sorscher
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme.

Authors:  G N Smith; E A Mickler; K A Hasty; K D Brandt
Journal:  Arthritis Rheum       Date:  1999-06

3.  Bioactivity of peptide analogs of the neutrophil chemoattractant, N-acetyl-proline-glycine-proline.

Authors:  J L Haddox; R R Pfister; D D Muccio; M Villain; C I Sommers; M Chaddha; G M Anantharamaiah; W J Brouillette; L J DeLucas
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

4.  Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis.

Authors:  Philippe E Van den Steen; Paul Proost; Bernard Grillet; David D Brand; Andrew H Kang; Jo Van Damme; Ghislain Opdenakker
Journal:  FASEB J       Date:  2002-03       Impact factor: 5.191

5.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage.

Authors:  R C Billinghurst; L Dahlberg; M Ionescu; A Reiner; R Bourne; C Rorabeck; P Mitchell; J Hambor; O Diekmann; H Tschesche; J Chen; H Van Wart; A R Poole
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Chemotactic activity of elastin-derived peptides.

Authors:  R M Senior; G L Griffin; R P Mecham
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

Review 7.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.

Authors:  Jonathan S Rosenblum; John W Kozarich
Journal:  Curr Opin Chem Biol       Date:  2003-08       Impact factor: 8.822

8.  A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation.

Authors:  Nathaniel M Weathington; Anneke H van Houwelingen; Brett D Noerager; Patricia L Jackson; Aletta D Kraneveld; F Shawn Galin; Gert Folkerts; Frans P Nijkamp; J Edwin Blalock
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

9.  The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis.

Authors:  Gülnur Emingil; Gül Atilla; Timo Sorsa; Hanne Luoto; Levent Kirilmaz; Haluk Baylas
Journal:  J Periodontol       Date:  2004-01       Impact factor: 6.993

Review 10.  The role of neutrophil elastase in chronic inflammation.

Authors:  G Döring
Journal:  Am J Respir Crit Care Med       Date:  1994-12       Impact factor: 21.405

View more
  142 in total

Review 1.  The impact of the extracellular matrix on inflammation.

Authors:  Lydia Sorokin
Journal:  Nat Rev Immunol       Date:  2010-10       Impact factor: 53.106

Review 2.  Neutrophils cascading their way to inflammation.

Authors:  Christian D Sadik; Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2011-08-11       Impact factor: 16.687

Review 3.  Integrated extracellular matrix signaling in mammary gland development and breast cancer progression.

Authors:  Jieqing Zhu; Gaofeng Xiong; Christine Trinkle; Ren Xu
Journal:  Histol Histopathol       Date:  2014-03-28       Impact factor: 2.303

Review 4.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

Authors:  Nikolaos G Frangogiannis; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

5.  CD14 signaling reciprocally controls collagen deposition and turnover to regulate the development of lyme arthritis.

Authors:  Bikash Sahay; Anju Singh; Arumugam Gnanamani; Rebeca L Patsey; J Edwin Blalock; Timothy J Sellati
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  The mercurial nature of neutrophils: still an enigma in ARDS?

Authors:  Andrew E Williams; Rachel C Chambers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-06       Impact factor: 5.464

7.  A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Authors:  J Michael Wells; Patricia L Jackson; Liliana Viera; Surya P Bhatt; Joshua Gautney; Guy Handley; R Wilson King; Xin Xu; Amit Gaggar; William C Bailey; Mark T Dransfield; J Edwin Blalock
Journal:  Am J Respir Crit Care Med       Date:  2015-10-15       Impact factor: 21.405

Review 8.  Matrix remodeling in chronic lung diseases.

Authors:  Bon-Hee Gu; Matthew C Madison; David Corry; Farrah Kheradmand
Journal:  Matrix Biol       Date:  2018-03-17       Impact factor: 11.583

9.  Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.

Authors:  Preston E Bratcher; Steven M Rowe; Ginger Reeves; Tambra Roberts; Tomasz Szul; William T Harris; Rabindra Tirouvanziam; Amit Gaggar
Journal:  J Cyst Fibros       Date:  2015-03-11       Impact factor: 5.482

10.  The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation.

Authors:  Matthew T Hardison; F Shawn Galin; Christopher E Calderon; Uros V Djekic; Suzanne B Parker; Keith M Wille; Patricia L Jackson; Robert A Oster; K Randall Young; J Edwin Blalock; Amit Gaggar
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.